Clareo Health | A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients
A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genzyme, a Sanofi Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed colorectal cancer
Have failed therapy with an oxaliplatin and fluoropyrimidine containing regimen defined as:
Progression on or following treatment for metastatic colorectal cancer
Progression within 12 months of adjuvant chemotherapy for colorectal cancer
You may not be if
Previous treatment with small molecule tyrosine kinase inhibitors of VEGFR or EGFR eg, erlotinib, gefitinib. Prior monoclonal antibodies are permitted, eg, cetuximab, bevacizumab.
Previous adjuvant therapy with irinotecan within 12 months of randomization
More than one prior course of chemotherapy for treatment of metastatic colorectal cancer.
